Current and Potential Application of GnRH Agonists in Gynecologic Practice

J M Tzafettas, J Tzafettas
Annals of the New York Academy of Sciences · 2000 · vol. 900(1) , pp. 435–443 · doi:10.1111/j.1749-6632.2000.tb06258.x · PMID:10818434 · W2128342964
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

GnRH agonists are revolutionizing gynecologic practice by effectively treating various conditions, but long-term use requires add-back therapy to mitigate adverse effects like bone loss.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The development of GnRH-a (analogues or agonists) is a major leap forward in the treatment of various hormone-dependent diseases in medicine. Their introduction in reproductive endocrinology, in in vitro fertilization/embryo transfer (IVF/ET) and other assisted reproduction techniques had a revolutionary impact. They have been effective in other gynecologic conditions including fibroids, endometriosis, anovulatory disorders, precocious puberty, dysfunctional uterine bleeding, and operative hysteroscopy. Medical castration induced by GnRH-a has become first-line therapy in metastatic breast cancer. Their long-term use, though, has been associated with a variety of adverse effects such as bone loss and decreased cardioprotection. "Steroid add-back" therapy in these cases apparently is an effective alternative. It may allow their safe long-term application beyond 6 months, averting unpleasant side-effects and maintaining bone mass and cardioprotection.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Genital Diseases, Female Gonadotropin-Releasing Hormone Female Genital Diseases, Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Reproductive Techniques

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (38)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:13:41.710148+00:00
License: CC0 · commercial use OK